
Director · Tarsus Pharmaceuticals, Inc. · Common Stock
Open-market sale
$183K reported value · 57.0% of prior position
Disclosed 2 business days after execution (deadline: 2)
First recorded trade by this actor in this security
1 other actor traded the same direction within 14 days
No material company filing within 60 days after the trade
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 9 | Clase NeeraChief Commercial Officer | Grant or award | A | — 6,678 sh | Nov 5, 2026 traded Nov 3, 2026 | |
| 9 | Clase NeeraChief Commercial Officer | Grant or award | A | — 10.6K sh | Nov 5, 2026 traded Nov 3, 2026 | |
| 28 | Lin Elizabeth YeuChief Medical Officer | Open-market sale · 10b5-1 plan | SELL | $135K 1,590 sh | Sep 9, 2026 traded Sep 4, 2026 | |
| 20 | Azamian Bobak R.Director, President/CEO and Board Chair | Open-market sale · 10b5-1 plan | SELL | $641K 7,100 sh | Sep 9, 2026 traded Sep 4, 2026 | |
| 32 | Lin Elizabeth YeuChief Medical Officer | Open-market sale · 10b5-1 plan | SELL | $143K 1,590 sh | Sep 9, 2026 traded Sep 4, 2026 | |
| 20 | Azamian Bobak R.Director, President/CEO and Board Chair | Open-market sale · 10b5-1 plan | SELL | $265K 2,900 sh | Sep 9, 2026 traded Sep 4, 2026 | |
| 27 | Neervannan SeshadriChief Operating Officer | Open-market sale · 10b5-1 plan | SELL | $388K 4,564 sh | Sep 9, 2026 traded Sep 4, 2026 | |
| 31 | Lin Elizabeth YeuChief Medical Officer | Open-market sale · 10b5-1 plan | SELL | $458K 5,387 sh | Sep 9, 2026 traded Sep 4, 2026 | |
| 35 | Lin Elizabeth YeuChief Medical Officer | Open-market sale · 10b5-1 plan | SELL | $485K 5,386 sh | Sep 9, 2026 traded Sep 4, 2026 | |
| 9 | Goldberg Andrew D.Director | Grant or award | A | — 2,417 sh | Jun 29, 2026 traded Jun 25, 2026 | |
| 5 | Goodrich KatherineDirector | Grant or award | A | — 3,837 sh | Jun 29, 2026 traded Jun 25, 2026 | |
| 5 | Goodrich KatherineDirector | Grant or award | A | — 2,417 sh | Jun 29, 2026 traded Jun 25, 2026 | |
| 9 | Goldberg Andrew D.Director | Grant or award | A | — 3,837 sh | Jun 29, 2026 traded Jun 25, 2026 | |
| 18 | Azamian Bobak R.Director, President/CEO and Board Chair | Open-market sale · 10b5-1 plan | SELL | $281K 4,582 sh | Jun 22, 2026 traded Jun 17, 2026 | |
| 18 | Azamian Bobak R.Director, President/CEO and Board Chair | Open-market sale · 10b5-1 plan | SELL | $335K 5,418 sh | Jun 22, 2026 traded Jun 17, 2026 | |
| 21 | Goodrich KatherineDirector | Option exercise | M | — 2,954 sh | Jun 16, 2026 traded Jun 12, 2026 | |
| 9 | Goodrich KatherineDirector | Option exercise | M | — 2,954 sh | Jun 16, 2026 traded Jun 12, 2026 | |
| 46 | Mottiwala AzizChief Commercial Officer | Open-market sale | SELL | $298K 4,286 sh | Mar 19, 2026 traded Mar 17, 2026 | |
| 42 | Whitfield Dianne C.Chief Human Resources Officer | Open-market sale | SELL | $280K 4,029 sh | Mar 19, 2026 traded Mar 17, 2026 | |
| 42 | Wahl BryanGeneral Counsel | Open-market sale | SELL | $283K 4,231 sh | Mar 19, 2026 traded Mar 19, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $183,384
Goodrich Katherine filed this Form 4 reporting a open-market sale of TARS on Jun 15, 2026. It became public on Jun 17, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.